Robeco Institutional Asset Management B.V. Trims Position in Hims & Hers Health, Inc. $HIMS

Robeco Institutional Asset Management B.V. reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 49.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,049 shares of the company's stock after selling 11,807 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Hims & Hers Health were worth $601,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Northern Trust Corp raised its position in shares of Hims & Hers Health by 19.5% in the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company's stock worth $71,969,000 after buying an additional 397,310 shares during the period. Yong Rong HK Asset Management Ltd increased its holdings in Hims & Hers Health by 41.2% in the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock valued at $70,920,000 after purchasing an additional 700,100 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Hims & Hers Health during the first quarter valued at about $58,403,000. BIT Capital GmbH grew its stake in shares of Hims & Hers Health by 7.4% during the first quarter. BIT Capital GmbH now owns 1,642,493 shares of the company's stock valued at $48,536,000 after acquiring an additional 112,949 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Hims & Hers Health by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company's stock valued at $37,242,000 after acquiring an additional 15,339 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $506,060.50. Following the sale, the insider owned 169,940 shares of the company's stock, valued at approximately $8,581,970. The trade was a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Michael Chi sold 2,100 shares of the business's stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $56.52, for a total value of $118,692.00. Following the sale, the insider directly owned 291,439 shares in the company, valued at approximately $16,472,132.28. The trade was a 0.72% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,622,741 shares of company stock valued at $83,695,469. Company insiders own 13.71% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HIMS shares. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Weiss Ratings reiterated a "hold (c)" rating on shares of Hims & Hers Health in a research note on Saturday, September 27th. Finally, Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Reduce" and a consensus target price of $38.92.

Hims & Hers Health Stock Performance

HIMS opened at $58.12 on Thursday. The business's 50 day moving average is $51.19 and its 200-day moving average is $47.64. The stock has a market cap of $13.14 billion, a PE ratio of 72.65, a price-to-earnings-growth ratio of 3.92 and a beta of 2.25. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a twelve month low of $17.36 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business's quarterly revenue was up 72.6% on a year-over-year basis. During the same period last year, the firm posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.